Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 3/20 | 0.37 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.32 |
| ▸ | ACACB | O00763 | 2/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | HTR3A | P46098 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20148740 | 0.92 | HRH3 (0.41) | RETCCR2HRH3TYK2JAK3 | |
| SCHEMBL23126245 | 0.89 | RET (0.36) | RETCCR2TYK2JAK3GPR119 | |
| SCHEMBL23555165 | 0.86 | RET (0.38) | RETCCR2TYK2JAK3GPR119 | |
| SCHEMBL20148738 | 0.82 | CCR2 (0.36) | CCR2HRH3GPR119 | |
| SCHEMBL20154607 | 0.82 | RET (0.40) | RETCCR2TYK2JAK3GPR119 | |
| SCHEMBL12988305 | 0.81 | JAK3 (0.35) | RETCCR2TYK2JAK3GPR119 | |
| SCHEMBL21159010 | 0.80 | RET (0.34) | RETTYK2JAK3GPR119CTSL | |
| SCHEMBL13034559 | 0.78 | JAK3 (0.38) | RETTYK2JAK3GPR119PDE4D | |
| SCHEMBL24785486 | 0.78 | HTR3A (0.34) | RETTYK2JAK3GPR119CTSL | |
| SCHEMBL20153223 | 0.77 | RET (0.36) | RETCCR2HRH3TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180133200-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133200-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | RET 1/4885CCR2 1878/4885HRH3 1148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.